دورية أكاديمية
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
العنوان: | Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation |
---|---|
المؤلفون: | Sunnia T. Chen, Leylah Azali, Lindsay Rosen, Qiuhong Zhao, Tracy Wiczer, Marilly Palettas, John Gambril, Onaopepo Kola-Kehinde, Patrick Ruz, Sujay Kalathoor, Kerry Rogers, Adam Kittai, Michael Grever, Farrukh Awan, John C. Byrd, Jennifer Woyach, Seema A. Bhat, Daniel Addison |
المصدر: | Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-11 (2022) |
بيانات النشر: | BMC, 2022. |
سنة النشر: | 2022 |
المجموعة: | LCC:Diseases of the blood and blood-forming organs LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
مصطلحات موضوعية: | Hypertension, Cardiovascular events, Acalabrutinib, Cancer-targeted therapy, Cardio-oncology, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
الوصف: | Abstract Background Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel selective second (next)-generation BTKi therapy, acalabrutinib, is unknown. Methods Leveraging a large cohort of consecutive B cell cancer patients treated with acalabrutinib from 2014 to 2020, we assessed the incidence and ramifications of new or worsened hypertension [systolic blood pressure (SBP) ≥ 130 mmHg] after acalabrutinib initiation. Secondary endpoints were major cardiovascular events (MACE: arrhythmias, myocardial infarction, stroke, heart failure, cardiac death) and disease progression. Observed incident hypertension rates were compared to Framingham heart-predicted and ibrutinib-related rates. Multivariable regression and survival analysis were used to define factors associated with new/worsened hypertension and MACE, and the relationship between early SBP increase and MACE risk. Further, the effect of standard antihypertensive classes on the prevention of acalabrutinib-related hypertension was assessed. Results Overall, from 280 acalabrutinib-treated patients, 48.9% developed new/worsened hypertension over a median of 41 months. The cumulative incidence of new hypertension by 1 year was 53.9%, including 1.7% with high-grade (≥ 3) hypertension. Applying the JNC 8 cutoff BP of ≥ 140/90 mmHg, the observed new hypertension rate was 20.5% at 1 year, > eightfold higher than the Framingham-predicted rate of 2.4% (RR 8.5, P |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 1756-8722 |
Relation: | https://doaj.org/toc/1756-8722 |
DOI: | 10.1186/s13045-022-01302-7 |
URL الوصول: | https://doaj.org/article/d6745f39b574408fa6a4ea02615773a4 |
رقم الأكسشن: | edsdoj.6745f39b574408fa6a4ea02615773a4 |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 17568722 |
---|---|
DOI: | 10.1186/s13045-022-01302-7 |